comparemela.com

Latest Breaking News On - Guerbet - Page 3 : comparemela.com

Guerbet Announces Commercial Launch and First Patient Dosing of Elucirem™ (Gadopiclenol) Injection, a Novel New Macrocyclic GBCA for Use in Contrast-Enhanced Magnetic Resonance Imaging (MRI)

GUERBET: Guerbet: 2022 revenue

2022 revenue Activity Annual revenue: €753.3 million, up +2.9% (-1.1% at CER1); production lags at the Raleigh site weighed on activity Profitability 2022 EBITDA margin: confirmation of the announced

Guerbet Releases First Production Batch of Elucirem™ (Gadopiclenol) Injection, a Novel New Macrocyclic GBCA for Use in Contrast-Enhanced Magnetic Resonance Imaging (MRI)

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.